HELLS Antibody

Code CSB-PA868307HA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human tonsil tissue using CSB-PA868307HA01HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human colon cancer using CSB-PA868307HA01HU at dilution of 1:100

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) HELLS Polyclonal antibody
Uniprot No.
Target Names
HELLS
Alternative Names
FLJ10339 antibody; Helicase lymphoid specific antibody; Hells antibody; HELLS_HUMAN antibody; LSH antibody; Lymphoid specific helicase antibody; Lymphoid-specific helicase antibody; Nbla10143 antibody; PASG antibody; Proliferation associated SNF2 like protein antibody; Proliferation-associated SNF2-like protein antibody; SWI/SNF2 related matrix associated actin dependent regulator of chromatin subfamily A member 6 antibody; SWI/SNF2-related matrix-associated actin-dependent regulator of chromatin subfamily A member 6 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Lymphoid-specific helicase protein (550-600AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The HELLS Antibody (Product code: CSB-PA868307HA01HU) is Non-conjugated. For HELLS Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA868307HB01HU HELLS Antibody, HRP conjugated ELISA
FITC CSB-PA868307HC01HU HELLS Antibody, FITC conjugated
Biotin CSB-PA868307HD01HU HELLS Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, IHC
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plays an essential role in normal development and survival. Involved in regulation of the expansion or survival of lymphoid cells. Required for de novo or maintenance DNA methylation. May control silencing of the imprinted CDKN1C gene through DNA methylation. May play a role in formation and organization of heterochromatin, implying a functional role in the regulation of transcription and mitosis.
Gene References into Functions
  1. HELLS and CDCA7 comprise a bipartite nucleosome remodeling complex; immunodeficiency-centromeric instability-facial anomalies syndrome has a defective HELLS and CDCA7 bipartite nucleosome remodeling complex PMID: 29339483
  2. This study elucidates the molecular basis of the c-Myc/EGLN1-mediated induction of LSH expression that inhibits ferroptosis PMID: 28900510
  3. LSH is likely one of the mechanisms of genome instability underlying 5-hydroxymethylcytosine loss in cancer. PMID: 29109788
  4. High mRNA levels of HELLS is independent predictor of poor outcome in Renal Cell Carcinoma patients. PMID: 28069330
  5. Mutations in HELLS cause immunodeficiency-centromeric instability-facial anomalies syndrome type 4. PMID: 26216346
  6. Mutations of HELLS gene is associated with stomach and colorectal cancers. PMID: 25351940
  7. Upregulation of HELLS and UHRF1 is essential for the tumor phenotype. Also, these epigenetic regulators are important for the regulation of SYK. PMID: 25338120
  8. just as E2F3, HELLS is overexpressed in human tumours including prostate cancer, indicating that either factor may contribute to the malignant progression of tumours PMID: 22157815
  9. E2F1 plays a crucial role in transcriptional control of the human Lsh gene and the decrease of Lsh expression in senescent cells is related to the repression of E2F1 PMID: 21453717
  10. Data provide strong evidence that CEP55 and HELLS may be used in conjunction with FOXM1 as a biomarker set for early cancer detection and indicators of malignant conversion and progression. PMID: 20400365
  11. LSH serves as a recruiting factor for DNA methyltransferases and histone deacetylases to establish transcriptionally repressive chromatin which is perhaps further stabilized by DNA methylation at targeted loci PMID: 17967891
  12. These results suggest differences in cellular consequences of hypomethylation mediated by PASG during development compared to that in somatic cells. PMID: 18948754
  13. Lsh overexpression delays cell senescence by silencing p16(INK4a) in human fibroblasts. PMID: 19561196

Show More

Hide All

Involvement in disease
Immunodeficiency-centromeric instability-facial anomalies syndrome 4 (ICF4)
Subcellular Location
Nucleus.
Protein Families
SNF2/RAD54 helicase family
Tissue Specificity
Highly expressed in proliferative tissues such as adult thymus and testis, and expressed at lower levels in uterus, small intestine, colon, and peripheral blood mononuclear cells. Also expressed in neoplastic cell lines including those derived from myeloi
Database Links

HGNC: 4861

OMIM: 603946

KEGG: hsa:3070

STRING: 9606.ENSP00000239027

UniGene: Hs.463677

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*